Oxford Pharmascience is a drug development company that re-develops approved drugs using proprietary formulation technologies to make them better, safer and easier to take.
Since Oxford Pharmascience's products incorporate previously approved drugs, this reduces risk and results in a simplified drug development regulatory pathway allowing less expensive development programs and faster access to market.
The Company's pipeline is focused on cardiovascular disease and pain relief indications addressing unmet patient needs with significant commercial potential in global markets.
Developing improved formulations of non-steroidal anti-inflammatory drugs (NSAIDs):
OXP001 - Reduced Gastric Irritation Ibuprofen
OXP002 - Single, high dose, better tasting Oral Suspension Ibuprofen (OXP002)